Year1
- 型号：
- 吉非替尼片
- 规格：
- 0.25g*30片/盒
- 有效期：
- 24个月
The Indian company produced) Iressa Gefitinib Tablets
has a new packaging, which is more formal and easier to prevent counterfeiting! The newly packaged medicine is still a box of tablets, and one box is for one month's treatment. The efficacy is still the same and the price remains unchanged
The new version of Iressa Gefitinib Tablets
The packaging box is higher and has It has raised printing and added Hindi, the local language of India
The new packaging will not be imitated by counterfeit drug dealers in a short time, and the technology of the new packaging is not easy to imitate
New packaging and old packaging The difference is that English and Indian labels are added below the side of the package.
)Iressa (gefitinib)
is a new type of small molecular weight tumor treatment drug. Its mechanism of action is mainly to block conduction and inhibit the proliferation of tumor cells by inhibiting autophosphorylation. Achieve targeted therapy. It is mainly used clinically to treat locally advanced or metastatic non-small cells that have previously received chemotherapy
)Iressa (gefitinib)
Iressa (gefitinib) is a new type of small molecular weight tumor treatment drug. The mechanism is mainly to block conduction by inhibiting autophosphorylation, inhibit the proliferation of tumor cells, and achieve targeted therapy. Clinically, it is mainly used to treat locally advanced or metastatic non-small cell lung cancer that has received chemotherapy in the past. It is especially effective for lung adenocarcinoma. The efficacy for squamous cell carcinoma is lower than that for adenocarcinoma and alveolar carcinoma. However, a large amount of clinical data shows that according to lung cancer The actual situation of the patients: After treatment with Iressa (gefitinib), some patients with lung squamous cell carcinoma and other non-small cell lung cancer still have obvious effects and are well tolerated.
【Indications】
This product is suitable for the treatment of locally advanced or metastatic non-small cell lung cancer that has received chemotherapy before. Previous chemotherapy treatments mainly referred to platinum and docetaxel treatments.
The efficacy of patients with locally advanced or metastatic non-small cell lung cancer who have failed chemotherapy is established based on objective response rate indicators. There are no controlled studies showing clinical efficacy in improving disease-related symptoms and prolonging survival. Benefit. The existing data on the use of this product in the second-line treatment of non-small cell lung cancer are only based on uncontrolled clinical studies and need to be further confirmed by well-designed controlled clinical trials.
For the first-line treatment of non-small cell lung cancer, the results of two large randomized controlled clinical trials showed that platinum-based dual chemotherapy regimens did not show any benefit after treatment with this product. Therefore, gefitinib is not suitable for this kind of treatment.
[Usage and Dosage]
The recommended adult dose of this product is (tablets), taken orally once a day, on an empty stomach or with food.
[Manufacturer] Indian Pharmaceuticals Limited (India's largest pharmaceutical company) Iressa India
[Trade name] )Iressa
[Common name] ) Gefitinib< br/> [English name]
[Specifications] *Indian plates/bottles
[Storage] Below ℃, store in the original packaging (just keep it in a cool place indoors)
[Validity period] year
WhatsApp
